ArticleBlood advances2021
Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines.
Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline.British journal of haematology · 2024Guideline
- Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: A systematic review and network meta-analysis.Frontiers in immunology · 2022Pooled it
- Retreatment with R-CHOP-like therapy in patients with late relapse of diffuse large B-cell lymphoma.Blood advances · 2026Article
- Management of diffuse large B‑cell lymphoma in older adults: current strategies and emerging directions.Therapeutic advances in medical oncology · 2026Review
- Propensity-matched study of liposomal doxorubicin vs. doxorubicin in first-line DLBCL treatment: efficacy and safety.Frontiers in medicine · 2026Article
- Research on the correlation and potential mechanism of PKCδ expression with efficacy and prognosis in diffuse large B-cell lymphoma.Frontiers in oncology · 2026Article
- Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials.Blood cancer journal · 2025Article
- Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.HemaSphere · 2025Article
- Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure.Leukemia & lymphoma · 2025Article
- Diffuse Large B-Cell Lymphoma with Cardiac Metastasis: A Case Report.The American journal of case reports · 2025Article
- JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma5. Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS).International journal of hematology · 2025Article
- Review
- Validation and modification of simplified Geriatric Assessment and Elderly Prognostic Index: Effective tools for older patients with diffuse large B-cell lymphoma.Cancer medicine · 2024Article
- Reduced-Intensity Anthracycline-Free Chemoimmunotherapy in Elderly Patients With Newly Diagnosed or Relapsed Diffuse Large B-Cell Lymphoma.Journal of hematology · 2023Article
- Evolving therapeutic landscape of diffuse large B-cell lymphoma: challenges and aspirations.Discover oncology · 2023Review
- Article
- Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma.JAMA cardiology · 2023Article
- Primary Diffuse Large B-Cell Lymphoma of the Bone.Journal of hematology · 2023Article
- R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma.Blood cancer journal · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doxorubicin plays an integral role in the treatment of patients with diffuse large B-cell lymphoma (DLBCL) but can be associated with significant toxicity. Treatment guidelines of British Columbia (BC) Cancer recommend the substitution of etoposide for doxorubicin in standard-dose R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) (R-CEOP) for patients who have a contraindication to anthracyclines; however, it is unknown if this compromises treatment outcome. We identified all patients with newly diagnosed DLBCL who were treated in BC with curative intent with R-CEOP (n = 70) within the study period. Outcome in this population was compared with a 2:1 case-matched control group (n = 140) treated with R-CHOP and matched for age, clinical stage, and International Prognostic Index score. The 10-year time to progression and disease-specific survival were not significantly different for patients treated with R-CEOP compared with patients in the R-CHOP control group (53% vs 62% [P = .089] and 58% vs 67% [P = .251], respectively). The 10-year overall survival was lower in the R-CEOP group (30% vs 49%, P = .002), reflecting the impact of underlying comorbidities and frailty of this population. R-CEOP represents a useful treatment alternative for patients with DLBCL and an absolute contraindication to the use of anthracyclines, with curative potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.